Summary
Breathing And Wellness Webinar is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 1 registered trial linking Breathing And Wellness Webinar to Long COVID: 1 has completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 189 participants. Registered activity dates to 2021. The literature layer holds 37 publications for this pair: 8 systematic reviews, 8 clinical trial publications and 21 other publications. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
Long COVID / PASC is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 423 candidate agents are logged for Long COVID, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 37.5 (trials 2.5, literature 30.0, tier 5, approved bonus 0.0) |
| Registered trials | 1 total: 0 recruiting, 0 active / not yet recruiting, 1 completed, 0 other |
| Linked publications | 37 (21 other publications, 8 systematic reviews, 8 clinical trial publications) |
| Agent type | Other (Other / Unclassified) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Not recorded |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05139979 | Yogic Breathing and Guided Meditation for Long Covid Symptoms Beth Israel Deaconess Medical Center · 2021 | completed | Not applicable | 189 |
Published literature
- Clinical trial publication (PubMed validation search) PubMed record PMID 42301723
- Clinical trial publication (PubMed validation search) PubMed record PMID 42173973
- Clinical trial publication (PubMed validation search) PubMed record PMID 42012216
- Clinical trial publication (PubMed validation search) PubMed record PMID 41906071
- Clinical trial publication (PubMed validation search) PubMed record PMID 41840063
- Clinical trial publication (PubMed validation search) PubMed record PMID 41663412
- Clinical trial publication (PubMed validation search) PubMed record PMID 41512740
- Clinical trial publication (PubMed validation search) PubMed record PMID 40045527
- Review (PubMed validation search) PubMed record PMID 42320154
- Review (PubMed validation search) PubMed record PMID 41091675
- Review (PubMed validation search) PubMed record PMID 41003635
- Review (PubMed validation search) PubMed record PMID 40170623
- Review (PubMed validation search) PubMed record PMID 39900109
- Review (PubMed validation search) PubMed record PMID 39518632
- Review (PubMed validation search) PubMed record PMID 39388147
- Review (PubMed validation search) PubMed record PMID 39365220
- Case series (PubMed validation search) PubMed record PMID 40171061
- Case series (PubMed validation search) PubMed record PMID 39129752
- Case series (PubMed validation search) PubMed record PMID 37433720
- Case series (PubMed validation search) PubMed record PMID 37316403
- Case series (PubMed validation search) PubMed record PMID 36223120
- Case series (PubMed validation search) PubMed record PMID 35734081
- Case series (PubMed validation search) PubMed record PMID 33492400
- Case report (PubMed validation search) PubMed record PMID 41050528
- Case report (PubMed validation search) PubMed record PMID 39619281
- Case report (PubMed validation search) PubMed record PMID 39257640
- Case report (PubMed validation search) PubMed record PMID 37691104
- Case report (PubMed validation search) PubMed record PMID 37323003
- Case report (PubMed validation search) PubMed record PMID 37267198
- Systematic review (PubMed validation search) PubMed record PMID 41482169
- Systematic review (PubMed validation search) PubMed record PMID 41223394
- Systematic review (PubMed validation search) PubMed record PMID 41062137
- Systematic review (PubMed validation search) PubMed record PMID 40122540
- Systematic review (PubMed validation search) PubMed record PMID 40083165
- Systematic review (PubMed validation search) PubMed record PMID 39218998
- Systematic review (PubMed validation search) PubMed record PMID 38807958
- Systematic review (PubMed validation search) PubMed record PMID 37344767
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
Clinical notes: Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Frequently asked questions
Is Breathing And Wellness Webinar approved for Long COVID?
Breathing And Wellness Webinar is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Breathing And Wellness Webinar in clinical trials for Long COVID?
ClinicalTrials.gov lists 1 registered trial linking Breathing And Wellness Webinar to Long COVID: 1 has completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 189 participants. Registered activity dates to 2021.
What does the evidence show for Breathing And Wellness Webinar in Long COVID?
Breathing And Wellness Webinar has both completed registered trials and synthesis-level publications linked to Long COVID. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.